Product Information
EPCLUSA 400 MG-100 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $866.3988 per EA under NDC 61958220101. Its NADAC has been published 383 times since Feb 22, 2017.
FDA first approved this application on Jun 28, 2016.
Strength
400; 100 mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958220101
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
SOFOSBUVIR; VELPATASVIRApproval Type
New Drug (NDA)
FDA Application
NDA208341FDA Approved
6/28/2016
On Market Since
6/28/2016
Pharmacological Classes
Price Statistics
The NADAC for EPCLUSA 400 MG-100 MG TABLET has been published 383 times since Feb 22, 2017, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $866.3988 per EA |
|---|---|
| All-time high | $869.7970 (Apr 10, 2024) |
| All-time low | $852.5161 (Feb 22, 2017) |
| 52-week high | $867.2160 |
| 52-week low | $861.8399 |
| Median price | $867.7500 |
| Average price | $866.3626 |
| Largest weekly change | +1.0% (Oct 18, 2017) |
| Weeks tracked | 383 |
| Tracking since | Feb 22, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 68% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of EPCLUSA 400 MG-100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EPCLUSA 400 MG-100 MG TABLET, manufactured by Gilead Sciences, Inc., is $866.3988 per EA (NDC 61958220101), effective Aug 19, 2026.
How has the price of EPCLUSA 400 MG-100 MG TABLET changed over time?
Over the history we have for it, the NADAC for EPCLUSA 400 MG-100 MG TABLET has held within roughly two percent of its current level. It has been tracked across 383 weekly CMS publications since Feb 22, 2017.
What are the highest and lowest recorded NADAC prices for EPCLUSA 400 MG-100 MG TABLET?
Since Feb 22, 2017, the NADAC for EPCLUSA 400 MG-100 MG TABLET has ranged from a low of $852.5161 (Feb 22, 2017) to a high of $869.7970 (Apr 10, 2024), with a median of $867.7500 per EA.
Are there cheaper alternatives to EPCLUSA 400 MG-100 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SOFOSBUVIR-VELPATASVIR 400-100, is $278.0492 per EA — about 68% below EPCLUSA 400 MG-100 MG TABLET.
Who manufactures EPCLUSA 400 MG-100 MG TABLET?
EPCLUSA 400 MG-100 MG TABLET (NDC 61958220101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.